Eli Lilly’s retatrutide is under investigation in another six Phase III trials.

GLP-1 RAs may be associated with reduced risk for worsening mental illness in people with co-occurring diabetes, anxiety, and depression.

Some GLP-1 receptor agonists, particularly semaglutide, reduced the risk for worsening mental health in people with anxiety ...

Retatrutide is an investigational once-weekly triple hormone (glucose-dependent insulinotropic polypeptide, glucagon-like ...

In the Phase 3 ACHIEVE-3 trial, oral orforglipron demonstrated superior HbA1c and weight reduction vs oral semaglutide in ...

His research showed that Type 2 diabetes was caused by insulin resistance at the cellular level, a controversial idea that ...

No increased risk for preterm birth seen in association with periconceptional exposure to GLP-1 receptor agonists for weight ...

GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Consider two seemingly unrelated medical puzzles. First: Every day, our bodies produce hundreds of billions of new cells, ...